|
|||||
|
|
Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma |
|
| Authors: | Francisco Javier Peñalver Julio Delgado Javier Loscertales Jose Luis Sastre Asunción Peña María Teresa Olave Santiago Osorio Adolfo de la Fuente Antonio Salar Carlos Grande Elena Pérez Ceballos Guillermo Debén Asunción Echeveste Felipe Casado Javier de la Rubia Juan José Lahuerta María Victoria Mateos |
| Affiliation: | 1. Department of Hematology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain;2. Department of Hematology, Hospital Clinic, Barcelona, Spain;3. Department of Hematology, Hospital Universitario de La Princesa, Madrid, Spain;4. Department of Hematology, Complexo Hospitalario de Ourense, Ourense, Spain;5. Department of Hematology, Hospital Universitario San Carlos, Madrid, Spain;6. Department of Hematology, Hospital Universitario Lozano Blesa, Zaragoza, Spain;7. Department of Hematology, Hospital Universitario Gregorio Mara?ón, Madrid, Spain;8. Department of Hematology, MD Anderson Cancer Center, Madrid, Spain;9. Department of Hematology, Hospital del Mar, Barcelona, Spain;10. Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain;11. Department of Hematology, Hospital Universitario Morales Messeguer, Murcia, Spain;12. Department of Hematology, Complexo Hospitalario de La Coru?a, La Coru?a, Spain;13. Department of Hematology, Hospital Universitario Donostia, San Sebastián, Spain;14. Department of Hematology, Hospital Virgen de la Salud, Toledo, Spain;15. Department of Hematology, Hospital Universitario Doctor Peset, Valencia, Spain;16. Department of Hematology, IBSAL‐Hospital Universitario de Salamanca, Salamanca, Spain |
| Abstract: | Bendamustine is an increasingly used hybrid alkylating agent that is active in lymphoid neoplasias via a novel mechanism of action. There are some pending questions about its use in clinical practice because of its developmental features. A consensus panel of several leading Spanish hematologists with broad experience in the clinical use of bendamustine has established recommendations for the management and treatment of hematological patients with bendamustine based on available clinical data and the experience of the participants. These recommendations address the dose and treatment regimen for different clinical indications, the management of toxicity, and support therapy. This article contains the conclusions of this consensus panel, which are intended to serve as guidelines for the use of bendamustine. |
| Keywords: | consensus bendamustine lymphoproliferative syndromes |